Open AccessRecommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi‐Stakeholder Think Tank
Author(s) -
Torok Rachel D.,
Li Jennifer S.,
Kannankeril Prince J.,
Atz Andrew M.,
Bishai Raafat,
Bolotin Ellen,
Breitenstein Stefanie,
Chen Cathy,
Diacovo Thomas,
Feltes Timothy,
Furlong Patricia,
Hanna Michael,
Graham Eric M.,
Hsu Daphne,
Ivy D. Dunbar,
Murphy Dianne,
Kammerman Lisa A.,
Kearns Gregory,
Lawrence John,
Lebeaut Brigitte,
Li Danshi,
Male Christoph,
McCrindle Brian,
Mugnier Pierre,
Newburger Jane W.,
Pearson Gail D.,
Peiris Vasum,
Percival Lisa,
Pina Miriam,
Portman Ronald,
Shaddy Robert,
Stockbridge Norman L.,
Temple Robert,
Hill Kevin D.
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.007283
Subject(s) - medicine , drug development , drug , stakeholder , intensive care medicine , pharmacology , public relations , political science
Children have historically been underrepresented or, indeed, omitted entirely, in drug trials, leading to a relative dearth of evidence in support of appropriate drug treatments for many pediatric diseases.[1][1], [2][2] Recent legislative initiatives in the United States and the European Union (EU